Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Naohiro Tochikura"'
Autor:
Nobuhiro Ooba, Rira Iwahashi, Akiko Nogami, Toshimitsu Nakayama, Atsushi Kanno, Naohiro Tochikura, Susumu Ootsuka, Noriyasu Fukuoka
Publikováno v:
PLoS ONE, Vol 15, Iss 8, p e0237617 (2020)
Some findings on the association between glaucoma and statins in the Asian population have been reported. We conducted a retrospective cohort study using health insurance claims data maintained by the JMDC Inc., which comprises data on about three mi
Externí odkaz:
https://doaj.org/article/e1a671d5b4b1420888797c386620cd18
Autor:
Sakae Fukushima, Manami Oishi, Hiroya Aso, Kifumi Arai, Yuuki Sasaki, Naohiro Tochikura, Susumu Ootsuka, Noriyasu Fukuoka, Nobuhiro Ooba, Norikazu Kikuchi
Publikováno v:
European Journal of Hospital Pharmacy; Jul2023, Vol. 30 Issue 4, p208-213, 6p
Autor:
Naohiro Tochikura, Chiaki Matsumoto, So Iwabuchi, Hiroya Aso, Sakae Fukushima, Susumu Ootsuka, Nobuhiro Ooba, Masaki Ishihara, Hideto Nakajima, Hiroshi Umemura, Tomohiro Nakayama
Publikováno v:
European Journal of Hospital Pharmacy. :ejhpharm-2022
Autor:
Takahiro Nakayama, Makoto Makishima, Naohiro Tochikura, Yoshikazu Yoshida, So Iwabuchi, Takako Sakaue, Norikazu Kikuchi, Toru Imai, Masao Sekimoto, Shinichiro Suzuki, Masayuki Chuma, Tsukasa Kuwana, Kosaku Kinoshita, Nami Sawada
Publikováno v:
European Journal of Clinical Pharmacology. 75:929-937
It is important to accurately estimate accurate vancomycin (VCM) clearance (CLvcm) for appropriate VCM dosing in the treatment of patients with sepsis. However, the pathophysiology of sepsis can make CLvcm prediction less accurate. Clearance of hydro
Autor:
Makoto Makishima, Nami Sawada, Yoshikazu Yoshida, Masayuki Chuma, Kosaku Kinoshita, Shinichiro Suzuki, Toru Imai, Tomohide Komatsu, Norikazu Kikuchi, Tsukasa Kuwana, Takako Sakaue, Naohiro Tochikura
Publikováno v:
Therapeutic Drug Monitoring. 40:109-114
BACKGROUND Appropriate initial dosing of vancomycin (VCM) is important in improving survival and in preventing nephrotoxicity in critically ill patients, but the potential relationship between initial VCM trough levels and early-onset nephrotoxicity
Autor:
Norikazu Kikuchi, Yoshikazu Yoshida, Naohiro Tochikura, Nami Sawada, Kosaku Kinoshita, Shinichiro Suzuki, Toru Imai, Tsukasa Kuwana, Masayuki Chuma, Makoto Makishima
Publikováno v:
Proceedings for Annual Meeting of The Japanese Pharmacological Society. :PO2-14
Autor:
Yuuki Sasaki, Susumu Ootsuka, Norikazu Kikuchi, Kifumi Arai, Naohiro Tochikura, Manami Oishi, Hiroya Aso, Sakae Fukushima, Noriyasu Fukuoka, Nobuhiro Ooba
Publikováno v:
European Journal of Hospital Pharmacy. :ejhpharm-2021
Objective To examine the effect of angiotensin II receptor blocker (ARB) treatment on serum potassium level and hyperkalaemia risk in a clinical setting with inpatients and outpatients using calcium channel blockers (CCBs) as a reference standard. Me
Autor:
Akiko Nogami, Noriyasu Fukuoka, Toshimitsu Nakayama, Nobuhiro Ooba, Rira Iwahashi, Naohiro Tochikura, Atsushi Kanno, Susumu Ootsuka
Publikováno v:
PLoS ONE, Vol 15, Iss 8, p e0237617 (2020)
PLoS ONE
PLoS ONE
Some findings on the association between glaucoma and statins in the Asian population have been reported. We conducted a retrospective cohort study using health insurance claims data maintained by the JMDC Inc., which comprises data on about three mi
Autor:
Takahiro Nakayama, Masayuki Chuma, Naohiro Tochikura, So Iwabuchi, Shinichiro Suzuki, Chiaki Matsumoto, Toru Imai, Takashi Hamada, Masaru Nakagawa, Hiromichi Takahashi, Yoshihito Uchino, Katsuhiro Miura, Noriyoshi Iriyama, Yoshihiro Hatta, Masami Takei, Takahisa Kimura
Publikováno v:
Therapeutic Drug Monitoring; Feb2020, Vol. 42 Issue 1, p133-138, 6p
Autor:
Naohiro Tochikura, Yoshikazu Yoshida, Toru Imai, Makoto Makishima, Kosaku Kinoshita, Masayuki Chuma, Norikazu Kikuchi, Takako Sakaue, Morio Kaburaki
Publikováno v:
Clinical therapeutics. 38(12)
Vancomycin (VCM) is used in the treatment of methicillin-resistant Staphylococcus aureus infection. The dosage of VCM must be adjusted by using therapeutic drug monitoring because of the drug's narrow therapeutic concentration window. Although optima